WO2005023311A3 - Novel targets for the treatment of retina diseases - Google Patents

Novel targets for the treatment of retina diseases Download PDF

Info

Publication number
WO2005023311A3
WO2005023311A3 PCT/EP2004/010785 EP2004010785W WO2005023311A3 WO 2005023311 A3 WO2005023311 A3 WO 2005023311A3 EP 2004010785 W EP2004010785 W EP 2004010785W WO 2005023311 A3 WO2005023311 A3 WO 2005023311A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
novel targets
oat2
oat4
usag
Prior art date
Application number
PCT/EP2004/010785
Other languages
French (fr)
Other versions
WO2005023311A2 (en
Inventor
Den Berghe Loic Van
Karine Sainton
Dominique Marchant
Stephanie Gadin
Maurice Menasche
Marc Abitbol
Original Assignee
Ass Francaise Retinitis Pigmen
Univ Paris Descartes
Den Berghe Loic Van
Karine Sainton
Dominique Marchant
Stephanie Gadin
Maurice Menasche
Marc Abitbol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ass Francaise Retinitis Pigmen, Univ Paris Descartes, Den Berghe Loic Van, Karine Sainton, Dominique Marchant, Stephanie Gadin, Maurice Menasche, Marc Abitbol filed Critical Ass Francaise Retinitis Pigmen
Priority to AU2004269920A priority Critical patent/AU2004269920A1/en
Publication of WO2005023311A2 publication Critical patent/WO2005023311A2/en
Publication of WO2005023311A3 publication Critical patent/WO2005023311A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to novel treatments of ocular diseases. In particular, the invention provides methods of treating a retinal disorder in a mammal comprising modulating the amount of a polypeptide encoded by a gene selected among the group consisting of prosaposin, TMS-2, OAT1, OAT2, OAT3, OAT4, USAG-1, SOST and Pcdh-Ϝ-C3 genes, in a retinal cell. The invention also relates to methods of diagnosing a retinal disorder comprising identitying an abnormal expression of a gene selected among the group consisting of prosaposin, TMS-2, OAT1, OAT2, OAT3, OAT4, USAG-1, SOST and Pcdh-Ϝ-C3 genes.
PCT/EP2004/010785 2003-09-11 2004-09-10 Novel targets for the treatment of retina diseases WO2005023311A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004269920A AU2004269920A1 (en) 2003-09-11 2004-09-10 Novel targets for the treatment of retina diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50212303P 2003-09-11 2003-09-11
US60/502,123 2003-09-11

Publications (2)

Publication Number Publication Date
WO2005023311A2 WO2005023311A2 (en) 2005-03-17
WO2005023311A3 true WO2005023311A3 (en) 2005-11-17

Family

ID=34273084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010785 WO2005023311A2 (en) 2003-09-11 2004-09-10 Novel targets for the treatment of retina diseases

Country Status (2)

Country Link
AU (1) AU2004269920A1 (en)
WO (1) WO2005023311A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN108330175A (en) * 2017-09-29 2018-07-27 中国医学科学院医学生物学研究所 The method that RT-qPCR detects macaque SLC22A11/OAT4 gene transcription levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004262A1 (en) * 1997-07-17 1999-01-28 Myelos Neurosciences Corporation Prosaposin receptor assay

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004262A1 (en) * 1997-07-17 1999-01-28 Myelos Neurosciences Corporation Prosaposin receptor assay
US20020019014A1 (en) * 1997-07-17 2002-02-14 Parks D. Elliot Methods of identifying prosaposin receptor agonists and antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D'CRUZ P M ET AL: "Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat.", HUMAN MOLECULAR GENETICS. 1 MAR 2000, vol. 9, no. 4, 1 March 2000 (2000-03-01), pages 645 - 651, XP002318940, ISSN: 0964-6906 *
FIELDEN MARK R ET AL: "Gestational and lactational exposure of male mice to diethylstilbestrol causes long-term effects on the testis, sperm fertilizing ability in vitro, and testicular gene expression.", ENDOCRINOLOGY. AUG 2002, vol. 143, no. 8, August 2002 (2002-08-01), pages 3044 - 3059, XP002318937, ISSN: 0013-7227 *
JACOBS K A ET AL: "A genetic selection for isolating cDNAs encoding secreted proteins.", GENE. 1 OCT 1997, vol. 198, no. 1-2, 1 October 1997 (1997-10-01), pages 289 - 296, XP002318939, ISSN: 0378-1119 *
SHEEDLO HAROLD J ET AL: "Expression of p75(NTR) in photoreceptor cells of dystrophic rat retinas.", BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH. 30 JUN 2002, vol. 103, no. 1-2, 30 June 2002 (2002-06-30), pages 71 - 79, XP002318938, ISSN: 0169-328X *
VAN DEN BERGHE LOÏC ET AL: "Prosaposin gene expression in normal and dystrophic RCS rat retina.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. MAY 2004, vol. 45, no. 5, May 2004 (2004-05-01), pages 1297 - 1305, XP009043908, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
AU2004269920A1 (en) 2005-03-17
WO2005023311A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
Guo et al. Gene expression signatures in tree shrew sclera in response to three myopiagenic conditions
Marchetti et al. Methionine sulfoxide reductases B1, B2, and B3 are present in the human lens and confer oxidative stress resistance to lens cells
WO2002082904A3 (en) Method of treating or retarding the development of blindness
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
WO2004007665A3 (en) Methods for inducing differentiation of embryonic stem cells and uses thereof
EP2438816A3 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2010048352A8 (en) Methods for treating eye disorders
WO2005003766A3 (en) Methods of regulating metabolism and mitochondrial function
WO2008013737A3 (en) Compositions for reprogramming a cell and uses therefor
WO2003039404A3 (en) Methods for treating ocular neovascular diseases
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2006062716A3 (en) Methods and compositions for treating ocular disorders
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
WO2006133022A3 (en) Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2008067040A3 (en) Method of detecting ocular diseases and pathologic conditions and treatment of same
He et al. Gene expression signatures in tree shrew choroid in response to three myopiagenic conditions
EP0859636A4 (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
WO2005117941A3 (en) Methods and compositions for the treatment of polycystic diseases
WO2008136670A3 (en) Improved methods and means for lentiviral gene delivery
Nucci et al. Multifaceted roles of nitric oxide in the lateral geniculate nucleus: from visual signal transduction to neuronal apoptosis
WO2005023311A3 (en) Novel targets for the treatment of retina diseases
KR20210091826A (en) Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia
WO2003055983A3 (en) Targeted retrograde gene delivery to motor neurons
WO2003030836A3 (en) Neuronal regeneration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004269920

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004269920

Country of ref document: AU

Date of ref document: 20040910

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004269920

Country of ref document: AU

122 Ep: pct application non-entry in european phase